YONDELIS
Total Payments
$5.3M
Transactions
1,156
Doctors
285
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $69,407 | 6 | 2 |
| 2023 | $192,915 | 6 | 0 |
| 2022 | $203,823 | 5 | 0 |
| 2021 | $17,789 | 2 | 0 |
| 2020 | $9,528 | 1 | 0 |
| 2019 | $317,047 | 25 | 1 |
| 2018 | $1.3M | 256 | 82 |
| 2017 | $3.2M | 855 | 229 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.1M | 471 | 95.4% |
| Consulting Fee | $192,218 | 67 | 3.6% |
| Food and Beverage | $20,753 | 547 | 0.4% |
| Travel and Lodging | $20,296 | 59 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,900 | 3 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $2,400 | 2 | 0.0% |
| Education | $108.22 | 7 | 0.0% |
Payments by Type
Research
$5.1M
471 transactions
General
$246,674
685 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Open-Label Study Comparing the Combination of YONDELIS? and DOXIL?/CAELYX? With DOXIL?/CAELYX? Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Janssen Research & Development, LLC | $4.1M | 0 |
| A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'Deoxy3'18F Fluorothymidine 18FFLT Imaging | Janssen Research & Development, LLC | $465,980 | 0 |
| R279741SAR0002 Pollack Immune Based Biomarkers For Trabectedin | Janssen Research & Development, LLC | $155,948 | 0 |
| A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Janssen Research & Development, LLC | $152,128 | 0 |
| A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma | Janssen Research & Development, LLC | $129,760 | 0 |
| An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin | Janssen Research & Development, LLC | $37,758 | 0 |
| R279741SAR0002 Immune Based Biomarkers For Trabectedin | Janssen Research & Development, LLC | $16,925 | 0 |
| A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment | Janssen Research & Development, LLC | $7,800 | 0 |
| A Study Comparing the Combination of Trabectedin YONDELIS and DOXILCAELYX With DOXILCAELYX for the Treatment of Advanced Relapsed Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer | Janssen Research & Development, LLC | $864.00 | 0 |
Top Doctors Receiving Payments for YONDELIS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | La Jolla, CA | $5.1M | 473 |
| , MD | Obstetrics & Gynecology | Philadelphia, PA | $18,104 | 25 |
| , MD | Gynecologic Oncology | Phoenix, AZ | $17,249 | 15 |
| , M.D., PH. D | Medical Oncology | Miami, FL | $15,919 | 23 |
| Alexander Olawaiye | Gynecologic Oncology | Pittsburgh, PA | $15,370 | 23 |
| Shreyaskumar Patel | Medical Oncology | Houston, TX | $15,288 | 20 |
| , M.D | Gynecologic Oncology | Cincinnati, OH | $13,261 | 12 |
| , MD | Hematology & Oncology | Philadelphia, PA | $10,745 | 8 |
| , M.D | Medical Oncology | Santa Monica, CA | $8,508 | 17 |
| , MD | Medical Oncology | Stanford, CA | $7,873 | 9 |
| , MD | Internal Medicine | Durham, NC | $7,609 | 11 |
| , M.D., PH.D | Medical Oncology | Aurora, CO | $7,580 | 9 |
| , MD | Internal Medicine | Atlanta, GA | $7,281 | 7 |
| , MD | Obstetrics & Gynecology | Detroit, MI | $6,956 | 13 |
| , M.D | Gynecologic Oncology | Miami, FL | $6,956 | 13 |
| , MD | Obstetrics & Gynecology | Oklahoma City, OK | $6,711 | 14 |
| , M.D | Specialist | Philadelphia, PA | $6,563 | 2 |
| , MD | Gynecologic Oncology | Miami, FL | $4,882 | 5 |
| , M.D | Obstetrics & Gynecology | Aurora, CO | $4,676 | 15 |
| , MD | Hematology & Oncology | New York, NY | $4,635 | 4 |
| , M.D | Specialist | Santa Monica, CA | $4,471 | 17 |
| , M.D | Gynecologic Oncology | Houston, TX | $3,621 | 9 |
| , MD, PHD | Hematology & Oncology | Los Angeles, CA | $3,450 | 3 |
| , MD | Hematology | Gainesville, FL | $3,305 | 8 |
| , M.D | Medical Oncology | Tampa, FL | $3,259 | 5 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $5.1M
- Janssen Products, LP $180,315
- Janssen Biotech, Inc. $31,893
- Janssen Scientific Affairs, LLC $15,096
- Janssen Pharmaceuticals, Inc $108.22
Product Information
- Type Drug
- Total Payments $5.3M
- Total Doctors 285
- Transactions 1,156
About YONDELIS
YONDELIS is a drug associated with $5.3M in payments to 285 healthcare providers, recorded across 1,156 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $69,407 was paid across 6 transactions to 2 doctors.
The most common payment nature for YONDELIS is "Unspecified" ($5.1M, 95.4% of total).
YONDELIS is associated with 9 research studies, including "A Randomized, Open-Label Study Comparing the Combination of YONDELIS? and DOXIL?/CAELYX? With DOXIL?/CAELYX? Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer" ($4.1M).